Used in the treatment of metastatic colorectal cancer and advanced gastrointestinal stromal tumors, Regorafenib Hydrochloride functions as a multikinase inhibitor that targets tumor angiogenesis, oncogenic signaling, and the tumor microenvironment. It helps slow down cancer progression by inhibiting multiple kinases involved in the growth and spread of tumor cells. It is typically prescribed when other standard therapies have failed, offering a later-line treatment option to extend survival in patients with advanced disease. The compound is also investigated for use in other solid tumors due to its broad kinase inhibition profile.